[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Epiomic Epidemiology Series: Fragile X Syndrome Forecast in 11 Major Markets 2016-2026

October 2016 | 44 pages | ID: EB9389DA705EN
Black Swan Analysis limited

US$ 6,150.00

E-mail Delivery (PDF), Hard Copy Mail Delivery

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Fragile X syndrome (FXS) is an X-linked dominant genetic disorder. It is caused by a defect in the fragile-X mental retardation 1 gene (FRM1); this defect prevents the FRM1 gene from expressing FMRP. The FMRP protein, most commonly found in the brain, is essential for normal cognitive development and female reproductive function. FXS is the leading genetically inherited cause of intellectual and developmental disability.

This report provides the current prevalent population for Fragile X Syndrome across 11 Major Markets (USA, France, Germany, Italy, Spain, UK, Australia, Japan, Brazil, India and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Fragile-X have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Features associated with Fragile X Syndrome include:
  • Autistic-like features
  • Fragile X tremor ataxia syndrome (FXTAS)
  • Fragile X primary ovarian insufficiency (FXPOI)
  • Attention problems
  • Anxiety
  • Hyperactivity
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
  • Able to quantify patient populations in the global Fragile X Syndrome market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Fragile X Syndrome and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Fragile X Syndrome‚Äôs prevalent population.
  • Identify sub-populations within Fragile-x which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Fragile-x patients.

List of Tables and Figures
Introduction
Cause of the Disease
Risk Factors & Prevention
Diagnosis of the Disease
Variation by Geography/Ethnicity
Disease Prognosis & Clinical Course
Key comorbid conditions/Features associated with the disease
Methodology for quantification of patient numbers
  Impact of HPV vaccination
    Additional data available on request
Top-line prevalence for Cervical Cancer
Stage of Cervical Cancer patients
Histopathology of Cervical Cancer patients
Abbreviations used in the report
Other Black Swan Analysis Publications
Black Swan Analysis Online Patient-Based Databases
Patient-Based Offering
Online Pricing Data and Platforms
References
Appendix

LIST OF TABLES

HPV type and disease association with cervical cancer
HPV vaccines currently available
The Bethesda Classification System for cervical squamous cell dysplasia
FIGO staging of cervical cancer
5-year survival rate by stage of cervical cancer
Incidence of Cervical cancer, females (000s)
Cervical cancer patients by FIGO stage, females (000s)
Cervical cancer patients by histopathologic type, females (000s)
Abbreviations and Acronyms used in the report
USA Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
Canada Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
France Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
Germany Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
Italy Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
Spain Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
United Kingdom Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
Netherlands Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
Poland Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
Romania Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
Russia Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
Turkey Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
Australia Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
Japan Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
South Korea Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
China Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
India Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
Argentina Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
Brazil Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
Mexico Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
South Africa Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
Saudi Arabia Incidence of Cervical Cancer by 5-yr age cohort, females (000s)

LIST OF FIGURES

Profiles of Cervical cancer incidence by age
Incidence of Cervical cancer by country
Expected impact in Cervical cancer incidence due to HPV immunisation (UK)


More Publications